Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Inovio Pharmaceuticals (NASDAQ:INO) releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Inovio Pharmaceuticals' earnings report.
Earnings and Revenue
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Wall Street analysts see Inovio Pharmaceuticals reporting a loss of 30 cents per share on revenue of $7.5 million.
Inovio Pharmaceuticals EPS in the same period a year ago came in at a loss of 35 cents. Sales were $8.5 million. If the company were to match the consensus estimate, earnings would be up 14.29 percent. Revenue would be down 11.56 percent from the year-ago period.
In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
| Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
| EPS Estimate | -0.25 | -0.19 | -0.31 | -0.3 |
| EPS Actual | -0.4 | -0.13 | -0.31 | -0.35 |
Stock Performance
Over the last 52-week period, shares are down 32.24 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Inovio Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
The Inovio Pharmaceuticals's Q4 conference call is scheduled to begin at 8:00 a.m. ET and can be accessed here: http://ir.inovio.com/news-and-media/news/default.aspx
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.